
News|Videos|October 10, 2023
EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA
Advertisement
Please see full
Sponsored by AbbVie US Medical Affairs
Episodes in this series

This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Research suggests increasing labor induction prior to 39 weeks
2
Cervical cancer screening FAQs: Key updates from HRSA-supported guidelines
3
Thin evidence base for smartphone apps targeting perinatal mental health
4
Trump administration seeking pause on Louisiana lawsuit that could limit abortion pill access
5














